1 Introduction
2 Related Work
2.1 Information extraction
2.2 Topic model
2.3 Identifying technology emergence
3 Methodology
3.1 Data collection
Figure 1. A framework of data acquisition and analysis. |
3.2 Data preprocessing
Table 1. Criteria for distinguishing sentences. |
Sentences with academic innovation | Sentences that lack innovation |
---|---|
Introduce new ideas, unique approaches, or novel methods. | Furnish common background information or definitions. |
Display original discoveries, experimental results, or undocumented data. | Elucidate routine procedures and methods that are commonly used in this field. |
Propose unique applications, materials, or techniques. | Provide a summary of well-established information or results available in the literature. |
3.3 Information extraction (IE)
Table 2. BERT model hyperparameterization. |
Hyperparameter | Values | Description |
---|---|---|
batch_size | 32 | Number of samples per batch during training |
max_seq_length | 500 | Maximum length of input sequences |
learning_rate | 2e-5 | Learning rate, subject to tuning |
train_epochs | 20 | Number of training epochs |
warmup_proportion | 0.1 | Proportion of total training steps for learning rate warm-up |
adam_epsilon | 1e-8 | Epsilon value for the Adam optimizer |
dropout_prob | 0.1 | Dropout probability in dropout layers |
Figure 2. A framework of the BERT model. |
3.4 Topic identification
Figure 3. LDA (a) and TND (b) graphical models. |
3.5 Emerging technology identification
4 Results
4.1 BERT-based classification performance
Table 3. Model evaluation indicators. |
Model | Accuracy | Precision | Recall | F1 |
---|---|---|---|---|
BERT+ Classifier | 0.836 | 0.864 | 0.853 | 0.858 |
TF-IDF+SVM | 0.524 | 0.537 | 0.530 | 0.533 |
TF-IDF+KNN | 0.600 | 0.617 | 0.593 | 0.604 |
TF-IDF+NB | 0.582 | 0.553 | 0.569 | 0.560 |
Word2Vec+ SVM | 0.650 | 0.658 | 0.614 | 0.635 |
Word2Vec+ KNN | 0.696 | 0.628 | 0.603 | 0.615 |
Word2Vec+ NB | 0.623 | 0.609 | 0.634 | 0.621 |
Figure 4. Innovation sentence distribution trends. |
Table 4. Regional distribution of innovation indicators. |
Region | Average count | Percentage (%) |
---|---|---|
USA | 91.0 | 0.35 |
Australia | 89.5 | 0.40 |
Poland | 87.5 | 0.33 |
France | 86.5 | 0.44 |
Greece | 85.5 | 0.42 |
Iraq | 83.5 | 0.42 |
Denmark | 83.0 | 0.38 |
Jordan | 82.0 | 0.35 |
Kenya | 81.0 | 0.34 |
Hungary | 81.0 | 0.38 |
Malaysia | 79.0 | 0.38 |
India | 75.5 | 0.39 |
Mexico | 75.5 | 0.47 |
Thailand | 75.5 | 0.25 |
China | 74.5 | 0.40 |
Germany | 74.0 | 0.41 |
Nepal | 73.5 | 0.44 |
Brazil | 73.0 | 0.40 |
Italy | 71.0 | 0.37 |
Netherlands | 71.0 | 0.45 |
4.2 NLDA topic extraction results
Table 5. NLDA model hyperparameterization. |
Hyperparameter | Values | Description |
---|---|---|
num_topicsint | 20 | Number of topics |
Alphaint | 50 | Alpha parameter of TND |
Betafloat | 0.01 | Beta parameter of TND |
Iterationsint | 200 | Number of training iterations |
random_seed | 54 | Random seed to ensure consistent results |
Table 6 (a). NLDA Topic-Word Distribution. |
Topic 1: Nanostructures and Polymer Chemistry | Topic 2: Graphene and Nanocomposites in Drug Delivery | Topic 3: Nanomaterial Quality and Surface Properties | Topic 4: Nanoparticles in Cancer Research and Therapy | ||||
---|---|---|---|---|---|---|---|
Polymers | Structures | Bacteria | Diffraction | Nanoparticles | Solution | Nanoparticles | Treatment |
Nanoparticles | Nanostructures | Graphene | Surface | Nanomedicines | Surface | Transfection | Delivery |
Copolymer | Solution | Nanoparticles | Solution | Information | Factors | Migration | Concentration |
Treatment | Polymerization | Spectroscopy | Treatment | Product | Quality | Solution | Exosomes |
Surface | Polymerization | Nanocomposites | Coating | Treatment | Molecules | Pathway | Surface |
Topic 5: Ultrafast Centrifugation and Nanomaterial Preparation | Topic 6: Antitumor Therapy and Tumor Stem Cells | Topic 7: Nanoparticles and Drug Delivery | Topic 8: Photothermal Therapy and Nanomaterials in Cancer | ||||
Microscope | Centrifugation | Survival | Metastasis | Nanoparticles | Solubility | Cancer | Treatment |
Supernatant | Reagent | Resistance | Cancer | Curcumin | Solution | Nanoparticles | Conversion |
Nanoparticles | Solution | Chemotherapy | Treatments | Encapsulation | Content | Nanosheets | Photothermal |
Minutes | Transmission | Antitumor | Cancers | Hydrogel | Surface | Solution | Hypoxia |
Microplate | Concentration | Nanoparticles | Doxorubicin | Storage | Treatment | Species | Performance |
Topic 9: Antidiabetic Nanodrug Carriers and Biomedical Applications | Topic 10: Animal Studies and Biomedical Protocols | Topic 11: Nanoparticle Surface Characterization and Complex Structures | Topic 12: Inflammation and Biomaterial Interactions in Disease Research | ||||
Extract | Insulin | Animals | Staining | Adsorption | Solution | Inflammation | Solution |
Nanoparticles | Surface | Biodistribution | Committee | Nanoparticles | Treatment | Nanoparticles | Treatment |
Dendrimers | Delivery | Nanoparticles | Liver | Surface | Complexes | Macrophage | Responses |
Activities | Treatment | Sections | Solution | Nanotubes | Structures | Collagen | Surface |
Solution | Concentration | Group | Surface | Results | Material | Cytokines | Inflammatory |
Table 6 (b). NLDA Topic -Word Distribution. |
Topic 13: Nanotechnology in Vaccine Research and Infectious Diseases | Topic 14: Liposomes and Receptors in Drug Delivery | Topic 15: Nanoparticles in Materials Science | Topic 16: Nanocarriers for Hormone Release and Antitumor Drugs | ||||
---|---|---|---|---|---|---|---|
Nanoparticles | Treatment | Peptides | Affinity | Nanoparticles | Silicon | Nanocarriers | Loading |
Authors | Concentration | Antibodies | Solution | Channel | Treatment | Nanoparticles | Micelle |
Science | Diseases | Vesicles | Receptor | Solution | Diffusion | Carrier | Circulation |
Solution | Results | Nanoparticles | Membranes | Surface | Results | Dialysis | Prodrug |
Nanotechnology | Disease | Conjugation | Treatment | Parameters | Frequency | Antitumor | Solution |
Topic 17: Luminescence and Spectroscopy in Nanomaterials | Topic 18: Endocytosis and Cell Signaling with Nanoparticles | Topic 19: Methods for Nanoparticle Preparation and Purification | Topic 20: Nanoparticle Permeation Properties in Oncology Treatments | ||||
Emission | Wavelength | Internalization | Pathway | Dispersion | Product | Transport | Circulation |
Nanoparticles | Spectrum | Endocytosis | Nucleus | Nanoparticles | Solution | Nanoparticles | Solution |
Excitation | Signals | Nanoparticles | Surface | Centrifugation | Calibration | Penetration | Spheroids |
Resonance | Solution | Mechanisms | Treatment | Ethanol | Treatment | Vessels | Surface |
Resolution | Fluorescent | Solution | Pathways | Compound | Surface | Permeability | Treatment |
Table 7. LDA Topic -Word Distribution. |
Topic 1 | Topic 2 | Topic 3 | Topic 4 | Topic 5 | Topic 6 |
---|---|---|---|---|---|
protein | delivery | nanoparticles | nps | antibacterial | applications |
corona | cell | silver | nanoparticles | cells | properties |
cell | nanoparticles | agnps | delivery | bacteria | review |
proteins | review | activity | brain | activity | materials |
bone | drugs | nm | size | vivo | titanium |
Topic 7 | Topic 8 | Topic 9 | Topic 10 | Topic 11 | Topic 12 |
exosomes | based | tumor | wound | clinical | nanosheets |
cells | high | cancer | materials | cancer | surface |
tumour | cell | therapy | tissue | therapy | go |
nanoparticles | clinical | cells | healing | photothermal | mxenes |
drug | detection | pdt | bone | agents | applications |
4.3 Identification of emerging technology topics
Table 8 . Results of the calculation of thematic indicators. |
Innovation | Originality | Growth | Significance | Topic strength | Emerging degree | |
---|---|---|---|---|---|---|
Topic 12 | 0.793 | 0.446 | 0.390 | 0.913 | 1.000 | 0.722 |
Topic 8 | 1.000 | 0.489 | 0.698 | 0.507 | 0.567 | 0.614 |
Topic 6 | 0.632 | 0.591 | 0.616 | 0.709 | 0.375 | 0.595 |
Topic 4 | 0.580 | 0.296 | 1.000 | 0.592 | 0.499 | 0.569 |
Topic 2 | 0.145 | 0.566 | 0.191 | 0.730 | 0.777 | 0.533 |
Topic 16 | 0.557 | 0.769 | 0.581 | 0.359 | 0.426 | 0.529 |
Topic 9 | 0.351 | 0.342 | 0.144 | 0.882 | 0.376 | 0.474 |
Topic 7 | 0.530 | 0.315 | 0.391 | 0.709 | 0.284 | 0.465 |
Topic 3 | 0.272 | 0.000 | 0.342 | 1.000 | 0.256 | 0.427 |
Topic 5 | 0.403 | 1.000 | 0.426 | 0.103 | 0.180 | 0.417 |
Topic 13 | 0.310 | 0.217 | 0.379 | 0.768 | 0.046 | 0.383 |
Topic 15 | 0.000 | 0.124 | 0.000 | 0.777 | 0.609 | 0.363 |
Topic 11 | 0.090 | 0.213 | 0.360 | 0.753 | 0.044 | 0.343 |
Topic 14 | 0.292 | 0.238 | 0.222 | 0.684 | 0.071 | 0.341 |
Topic 1 | 0.264 | 0.263 | 0.262 | 0.506 | 0.268 | 0.334 |
Topic 18 | 0.208 | 0.479 | 0.238 | 0.540 | 0.000 | 0.333 |
Topic 10 | 0.329 | 0.758 | 0.404 | 0.000 | 0.246 | 0.330 |
Topic 20 | 0.358 | 0.089 | 0.206 | 0.705 | 0.117 | 0.328 |
Topic 17 | 0.216 | 0.332 | 0.447 | 0.392 | 0.156 | 0.318 |
Topic 19 | 0.273 | 0.544 | 0.255 | 0.127 | 0.007 | 0.242 |
Table 9. Emerging technologies in nanomedicine. |
Topic id | Topic meaning |
---|---|
12 | Inflammation and Biomaterial Interactions in Disease Research |
8 | Photothermal Therapy and Nanomaterials in Cancer |
6 | Antitumor Therapy and Tumor Stem Cells |
4 | Nanoparticles in Cancer Research and Therapy |
2 | Graphene and Nanocomposites in Drug Delivery |
16 | Animal Studies and Biomedical Protocols |
9 | Antidiabetic Nanodrug Carriers and Biomedical Applications |
7 | Nanoparticles and Drug Delivery |
Table 10. Emerging nanomedicine technology keywords classification. |
Category | Keywords |
---|---|
Nanomaterial Applications | Nanoparticles; Nanotubes; Nanofibers; Nanocrystals; Nanoshells; Metal nanoparticles (e.g.; Gold; Silver); Carbon nanomaterials (e.g.; Graphene; Fullerenes); Quantum dots; Polymeric nanoparticles; Nucleic acid Nanostructures |
Drug Delivery Systems | Drug-loaded nanoparticles; Nanomicelles; Nanoemulsions; Nanocapsules; liposomes; Polymeric drug conjugates; Targeted drug delivery; Controlled release systems; PH-responsive nanocarriers; Temperature-responsive nanocarriers |
Diagnostics and Imaging | Molecular imaging; Magnetic resonance imaging (MRI); Positron emission tomography (PET); Single photon emission computed tomography (SPECT); Optical imaging; Fluorescence imaging; Raman spectroscopy imaging; Upconversion nanoparticle imaging; Multimodal imaging |
Cancer diagnosis and treatment | Nanoparticles; Hypoxia therapy; Tumor-targeted therapy; Nano-immunomodulators |
Nanotherapy for infectious diseases | Nano-antimicrobials; Inflammation; Antimicrobial peptides; Nano-vaccines; Nano-antibiotics |
Rational Design of Antimicrobial Peptides | Antimicrobial peptides (AMPs); Peptide design; Membrane disruption mechanisms; Antibiotic resistance |